This was further supported by the phase III EMBRACA study which demonstrated that Talazoparib monotherapy had significantly greater PFS in patients with metastatic HER2-negative BRCA-mutated breast cancer in comparison to standard chemotherapy treatment (Litton et al., 2018). Here, ERBB2 is linked to breast carcinoma.